JAK2 and cancer: Based on the characteristics of the IL4Rα/IL13Rα1 receptor complex that is activated by both IL4 and IL13 and it stimulates the JAK1/JAK2/STAT6 pathway in solid cancers, IL4/IL13, IL4Rα/IL13Rα1, and JAK1/JAK2/STAT6 might be good therapeutic targets for the treatment of malignant tumors expressing IL4Rα/IL13Rα1.